KORU Medical Systems, Inc.

NASDAQ:KRMD

Medical - Instruments & Supplies

Healthcare
$3.45 +1.55%

+$0.06 today

Market cap
$149.64M
Beta
0.42
P/E (TTM)
-80.2
EPS (TTM)
-$0.05
52W Low $2.91High $6.61

Volume 0.19M

Average 0.13M

KRMD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

KORU Medical Systems, Inc.NASDAQ: KRMD

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$609.55K, compared with -$948.88K a year earlier. Trailing-twelve-month EBITDA was -$1.47M.

Context

  • EBITDA amounted to 4.4% of revenue in FY2025, down 11.3 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $700.43K (+138.8%) for the fiscal year ending Dec 2026, a step up from the +65.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$609.55K-101.2% QoQ
Last fiscal yearDec 2025
-$1.81M+65.9% YoY
LTMMar 2026
-$1.47M+67.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.8%-2151.3%-2187.1 pp
1 year+65.9%+138.8%+72.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(1.81M) USD
Year-over-year change
+65.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How KRMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +67.9% is the highest of 10, against a peer median of +5.7%.
  • EBITDA amounts to 3.4% of revenue for KRMD, versus a peer median of 46.7%.
KRMD Competitors
EBITDA for KRMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INFUInfuSystem Holdings, Inc.LTM Mar 2026$25.86M USD+21.2%+19.2%18.2%
UTMDUtah Medical Products, Inc.LTM Mar 2026$16.36M USD-9.1%-15.0%43.6%
KRMDKORU Medical Systems, Inc.LTM Mar 2026-$1.47M USD+67.9%—3.4%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026-$20.95M USD+5.5%—46.7%
STIMNeuronetics, Inc.LTM Mar 2026-$25.7M USD+34.0%—17.0%
MXCTMaxCyte, Inc.LTM Mar 2026-$34.64M USD+5.7%—107.3%
PROFProfound Medical Corp.LTM Mar 2026-$37.85M USD+9.1%—200.6%
PREPrenetics Global LimitedLTM Mar 2026-$51.68M USD+9.1%—45.4%
OSUROraSure Technologies, Inc.LTM Mar 2026-$63.7M USD-188.7%—56.4%
NYXHNyxoah S.A.LTM Mar 2026-€77.16M EUR-21.4%—472.8%
Peer median (excluding KRMD) —+5.7%+2.1%46.7%

Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.49M27.9M28.52M33.65M41.13M
Cost of Revenue9.72M12.53M11.81M12.31M15.52M
Gross Profit13.77M15.37M16.71M21.33M25.6M
Gross Margin58.6%55.1%58.6%63.4%62.3%
Research & Development2.47M4.96M5.74M5.26M4.39M
Selling, General & Admin000023.38M
Operating Expenses20.8M26.15M26.98M27.78M28.58M
Depreciation & Amortization463.13K587.14K870.39K772.89K810.5K
EBITDA(5.9M)(10.09M)(8.9M)(5.29M)(1.81M)
EBITDA Margin-25.1%-36.2%-31.2%-15.7%-4.4%
Operating Income(7.03M)(10.78M)(10.27M)(6.45M)(2.97M)
Operating Margin-29.9%-38.6%-36.0%-19.2%-7.2%
Interest Income13.08K145.59K561.33K444.64K293.4K
Interest Expense00000
Other Income / Expenses665.09K105.71K496.4K382.49K356.41K
Income Before Tax(6.36M)(10.68M)(9.77M)(6.06M)(2.62M)
Pre-Tax Margin-27.1%-38.3%-34.3%-18.0%-6.4%
Income Tax Expense(1.8M)(2.01M)3.97M2.89K21.89K
Net Income(4.56M)(8.66M)(13.74M)(6.07M)(2.64M)
Net Margin-19.4%-31.0%-48.2%-18.0%-6.4%
EPS (Basic)(0.10)(0.19)(0.30)(0.13)(0.06)
EPS (Diluted)(0.10)(0.19)(0.30)(0.13)(0.06)
Weighted Avg Shares44.39M45M45.6M45.8M46.19M
Weighted Avg Shares (Diluted)44.39M45M45.6M45.8M46.19M

KORU Medical Systems, Inc.

NASDAQ:KRMD

Intrinsic Alpha fair value

Locked

Current Price

$3.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.